SABS

SAB Biotherapeutics Inc

3.31

Nov 02 • 1:32 PM ET -0.04 (-1.13%)

Healthcare Biotechnology USA Small NASD

Peers: ELDN SANA CABA KYTX BMEA EQ ZURA IMVT IMUX ADMA

| Held by: VTI IWM VXF IWN VTWO IWC SBIO AVSC SURI VTWV

Index	RUT
Market Cap	301.34M
Enterprise Value	203.84M
Income	-38.87M
Sales	0.00M
Book/sh	2.57
Cash/sh	1.13
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	86
IPO	Feb 09, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.29
P/C	2.94
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.22
Current Ratio	9.22
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-1.66
EPS next Y	-0.80
EPS next Q	-0.27
EPS this Y	-53.58%
EPS next Y	33.95%
EPS next 5Y	2.38%
EPS past 3/5Y	43.07% -
Sales past 3/5Y	- -
EPS Y/Y TTM	95.16%
Sales Y/Y TTM	-100.00%
EPS Q/Q	74.09%
Sales Q/Q	-
Earnings	Nov 05 BMO
EPS/Sales Surpr.	0.92% -

Insider Own	10.40%
Insider Trans	0.00%
Inst Own	72.84%
Inst Trans	0.82%
ROA	-28.97%
ROE	-34.27%
ROIC	-17.73%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	14.34%
SMA50	1.95%
SMA200	-9.93%
Trades

Shs Outstand	83.49M
Shs Float	81.53M
Short Float	5.89%
Short Ratio	8.89
Short Interest	4.80M
52W High	5.15 -35.69%
52W Low	2.44 35.74%
Volatility	7.66% 8.19%
ATR (14)	0.21
RSI (14)	58.69
Beta	0.68
Rel Volume	0.58
Avg Volume	539.93K
Volume	200,390

Perf Week	18.71%
Perf Month	11.14%
Perf Quarter	-13.97%
Perf Half Y	-10.24%
Perf YTD	-11.44%
Perf Year	1.91%
Perf 3Y	-66.88%
Perf 5Y	-96.39%
Perf 10Y	-
Recom	1.08
Target Price	11.75
Prev Close	3.35
Price	3.31
Change %	-1.13%

Consensus

Strong Buy

Avg. Price Target

$11.75

Implied Upside

+254.8%

Analysts10incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 24, 2026	Initiated	BBarclays	Overweight	$13	+292.5%
May 22, 2026	Initiated	CCitigroup	Buy	$11	+232.1%
May 20, 2026	Initiated	JJefferies	Buy	$11	+232.1%
Apr 02, 2026	Initiated	RRodman & Renshaw	Buy	$13	+292.5%
Dec 19, 2025	Initiated	GGuggenheim	Buy	$15	+352.9%
Sep 17, 2025	Initiated	LLeerink Partners	Outperform	$7	+111.4%
May 14, 2025	Resumed	HH.C. Wainwright	Buy	$10	+201.9%
Oct 09, 2024	Initiated	CCraig Hallum	Buy	$11	+232.1%
Aug 28, 2024	Initiated	OOppenheimer	Outperform	$12	+262.3%
Nov 05, 2021	Initiated	CChardan Capital Markets	Buy	$17	+413.3%

Oct-29-26 12:01PM	SAB Biotherapeutics Heads Into Q3 With Safeguard Enrollment Clock And Tzield Competition In Focus (Earnings Whispers)
08:30AM	SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET (GlobeNewswire)
Oct-14-26 08:30AM	SAB BIO to Participate in Chardan 10th Annual Healthcare Conference (GlobeNewswire) -7.09%
Oct-13-26 08:30AM	SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes (GlobeNewswire) -5.30%
Oct-01-26 08:30AM	SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress (GlobeNewswire)
08:30AM	Loading…
Sep-22-26 08:30AM	SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-01-26 08:30AM	SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-06-26 07:14PM	SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... (GuruFocus.com)
07:30AM	SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-30-26 08:30AM	SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET (GlobeNewswire)
Jul-07-26 08:00AM	Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes (GlobeNewswire)
May-29-26 08:00AM	SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting (GlobeNewswire)
May-12-26 07:03PM	SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +9.39%
07:30AM	SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
May-05-26 08:30AM	SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET (GlobeNewswire)
07:00AM	Loading…
Apr-22-26 07:00AM	SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 (GlobeNewswire)
Apr-15-26 08:00AM	SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress (GlobeNewswire)
Mar-19-26 04:01PM	SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Mar-17-26 10:46PM	SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.09%
04:01PM	SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Mar-10-26 07:31AM	SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes (GlobeNewswire) +6.77%
Mar-09-26 05:16PM	SAB BIO Reports Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
Mar-02-26 09:00AM	SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-01-26 02:43PM	SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf (MarketBeat)
Feb-15-26 01:05AM	SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026 (MarketBeat)
Feb-04-26 09:00AM	SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-25-26 06:05AM	Analysts Predict Up to 400% Spike for These 2 Strong Buy Penny Stocks (TipRanks)
Jan-07-26 08:00AM	SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director (GlobeNewswire) +9.67%
Jan-06-26 08:00AM	SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-25 08:00AM	First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D (GlobeNewswire)
08:00AM	Loading…
Dec-17-25 08:00AM	SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D (GlobeNewswire)
Dec-08-25 08:00AM	SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management (GlobeNewswire) -10.80%
Nov-13-25 05:00PM	SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights (GlobeNewswire) -9.09%
Nov-04-25 08:30AM	SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 (GlobeNewswire)
08:00AM	SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-19-25 07:24AM	SAB BIO Highlights Data in Multiple Presentations at EASD (GlobeNewswire) -11.47%
Sep-03-25 04:05PM	SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.43%
Aug-07-25 10:00AM	SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
07:30AM	SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates (GlobeNewswire)
Jul-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.06%
07:30AM	SAB BIO Announces Oversubscribed $175 Million Private Placement (GlobeNewswire)
May-09-25 09:00AM	SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates (GlobeNewswire)
May-08-25 06:10PM	Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Mar-31-25 07:32AM	SAB BIO Reports Full Year 2024 Operating and Financial Results (GlobeNewswire) -8.11%
Jan-31-25 07:00AM	SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-25 07:00AM	SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 (GlobeNewswire) -52.52%
Jan-23-25 07:00AM	SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy (GlobeNewswire)
Nov-15-24 09:50AM	These 2 Strong Buy Penny Stocks Are Set to Triple (or more), Say Analysts (TipRanks) -16.22%
Nov-06-24 05:05PM	SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire) -17.22%
Oct-31-24 07:00AM	SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Sep-13-24 07:00AM	SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-24 07:00AM	SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting (GlobeNewswire)
Sep-04-24 07:05AM	SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting (GlobeNewswire)
Aug-08-24 05:51PM	SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates (GlobeNewswire) -12.91%
Aug-05-24 07:30AM	SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes (GlobeNewswire)
Jul-31-24 07:30AM	SAB BIO Appoints Lucy To as Chief Financial Officer (GlobeNewswire)
Jun-20-24 07:20AM	SAb Biotherapeutics Rebrands as SAB BIO (GlobeNewswire) +7.36%
Jun-18-24 01:10PM	SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions (GlobeNewswire) -20.62%
May-30-24 04:45PM	SAB Biotherapeutics Announces Departure of Chief Financial Officer (GlobeNewswire) -6.38%
May-21-24 09:53AM	SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024 (InvestorPlace) -15.65%
07:15AM	FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics (GlobeNewswire)
May-20-24 05:45PM	SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates (GlobeNewswire)
May-06-24 07:15AM	SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors (GlobeNewswire)
Apr-16-24 07:15AM	SAB Biotherapeutics Provides SAB-142 Trial Update (GlobeNewswire) +5.86%
Apr-08-24 07:15AM	SAB Biotherapeutics to Present at INNODIA Annual Meeting (GlobeNewswire)
Apr-04-24 07:15AM	SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-29-24 07:15AM	SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results (GlobeNewswire)
Mar-25-24 10:15AM	SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment (GlobeNewswire) -12.91%
Feb-23-24 08:00AM	SAB Biotherapeutics to Present at the BIO CEO & Investor Conference (GlobeNewswire)
Feb-08-24 08:00AM	SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-24 07:30AM	SAB Biotherapeutics Announces Executive Leadership Change (GlobeNewswire)
Jan-23-24 05:58PM	SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jan-02-24 04:30PM	SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Nov-29-23 01:29PM	SAB Biotherapeutics Starts Human Clinical Trial of Diabetes Treatment (Exec Edge) -5.43%
07:30AM	SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes (GlobeNewswire)
Nov-20-23 07:30AM	SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors (GlobeNewswire)
Nov-14-23 01:35PM	SAB Biotherapeutics 3Q Loss Narrows, Completes $67.1M in Financing (Exec Edge)
07:30AM	SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes (GlobeNewswire)
07:15AM	SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates (GlobeNewswire)
Nov-09-23 07:30AM	SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference (GlobeNewswire)
Oct-24-23 07:30AM	SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer (GlobeNewswire)
Oct-19-23 07:30AM	SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes (GlobeNewswire) +28.53%
Oct-05-23 07:30AM	SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors (GlobeNewswire)
Oct-03-23 11:31AM	SAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes Treatment (Exec Edge)
Oct-02-23 07:30AM	SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes (GlobeNewswire)
Aug-21-23 08:30AM	SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results (GlobeNewswire)
Jul-12-23 11:04AM	Swiss Franc Jumps to Highest Against Dollar Since SNB Lifted Cap (Bloomberg)
Jun-21-23 08:30AM	SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023 (GlobeNewswire)
May-30-23 08:30AM	SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention (GlobeNewswire)
May-19-23 08:30AM	SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations (GlobeNewswire)
May-16-23 08:30AM	SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results (GlobeNewswire) -11.36%
May-12-23 08:30AM	SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies (GlobeNewswire)
May-09-23 08:30AM	SAB Biotherapeutics Announces Progress on U.S. FDAs Phased Review of Companys Groundbreaking DiversitAb Platform (GlobeNewswire) -6.22%
07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-04-23 08:30AM	SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference (GlobeNewswire)
May-03-23 05:00PM	SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11 (GlobeNewswire)
Apr-26-23 08:30AM	SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications (GlobeNewswire) -6.90%
Apr-18-23 08:30AM	SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy (GlobeNewswire) +41.56%
Apr-13-23 08:30AM	SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza (GlobeNewswire) +99.71%

Show Previous News

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. It produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

CEO & DirectorMr. Samuel J. Reich

Co-FounderDr. Eddie Joe Sullivan Ph.D.

Executive VP & CFOMs. Lucy To

Ph.D.Dr. Christoph Bausch M.B.A.

M.D.Dr. Alexandra Kropotova M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SABS

SAB Biotherapeutics Inc

Upgrade your Finviz experience